Do not use ganirelix without first talking to your doctor if you have ever had an allergic reaction to this medication or to another gonadotropin-releasing hormone (GnRH) product such as goserelin (Zoladex) or gonadorelin (Factrel).
Before using ganirelix, tell your doctor if you have any other medical conditions or take any other medications. You may require a dosage adjustment or special monitoring during treatment.
Do not take ganirelix if you are pregnant. Ganirelix is in the FDA pregnancy category X. This means that ganirelix is known to be harmful to an unborn baby. Before starting treatment with ganirelix, it should be determined that you are not already pregnant.
It is not known whether ganirelix passes into breast milk. Do not take ganirelix without first talking to your doctor if you are breast-feeding a baby.
There are no restrictions on food, beverages, or activity during treatment with ganirelix, unless otherwise directed by your doctor.
An overdose of ganirelix is unlikely to threaten life. Notify your doctor immediately or call an emergency room or poison control center for advice if an overdose is suspected.
Symptoms of a ganirelix overdose are not known.
It is important not to miss a dose of ganirelix. Contact your doctor immediately if you miss a dose of this medication.
Ovarian hyperstimulation syndrome (OHSS) is an uncommon complication of treatment with ganirelix and other fertility medications. Symptoms of OHSS include severe pelvic pain, swelling of the hands or legs, abdominal pain and swelling, shortness of breath, weight gain, low urine output, diarrhea, severe nausea, and vomiting. OHSS can be fatal. Notify your doctor immediately or seek emergency medical attention if you develop any of these symptoms.
Seek emergency medical attention if you experience a rare but serious allergic reaction (difficulty breathing; closing of the throat; swelling of the lips, tongue, or face; or hives) to ganirelix.
Other side effects may also occur. Notify your doctor if you experience
- mild nausea;
- vaginal bleeding; or
- pain, redness, or irritation at the injection site.
Side effects other than those listed here may also occur. Talk to your doctor about any side effect that seems unusual or that is especially bothersome. You may report side effects to FDA at 1-800-FDA-1088.
It is not known whether other medications will interact with ganirelix. Talk to your doctor and pharmacist before taking any prescription or over-the-counter medicines, including herbal products during treatment with ganirelix.
Antagon, Ganirelix Acetate, and ganirelix
Every effort has been made to ensure that the information provided by Cerner Multum, Inc. ('Multum') is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Multum information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Multum does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Multum's drug information does not endorse drugs, diagnose patients or recommend therapy. Multum's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Multum does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Copyright 1996-2004 Cerner Multum, Inc. Version 2.05. Revision date 8/23/04